- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03815019
iKanEat: A Randomized-controlled, Multi-center Trial of Megestrol for Chronic Oral Food Refusal in Children (iKanEat)
iKanEat: A Randomized-controlled, Multi-center Trial of Megestrol for Chronic Oral Food Refusal in Children 9 Months to 9 Years 0 Months of Age
Study Overview
Status
Intervention / Treatment
Detailed Description
The primary aim of the current study is to conduct a randomized controlled trial of a 4-week course of megestrol, the only remaining medication that is part of the iKanEat protocol, to ensure that the addition of megestrol results in improved child outcomes. The second aim is to assess the safety of megestrol as part of the iKanEat protocol. Our previous work (as well as work by others) suggests that a 6 week course of megestrol can lead to adrenal insufficiency in some children, so as part of the current protocol, the investigators will assess the safety of a 4 week course of this drug.
Finally, parents of tube fed children encounter multiple psychosocial stressors regarding tube feeding. These include concerns about their child's survival due to their underlying medical issues, feelings of "failure" due to their inability to feed their child orally, increased feelings of stress around the tube feeding and decreased support from others due to the tube feeding. Our research indicates that quality of life can be poor in tube fed children, even more so than children with cancer or burns. Given the significance of these issues, the third aim of the study is to examine the effect of the transition from tube to oral feeding on parent stress and parent and child quality of life.
Aim 1: To assess the efficacy of megestrol as part of the 24 week iKanEat protocol.
Hypothesis 1: Children randomized to the megestrol group will be significantly more successful in making the transition to oral feeding (defined as obtaining at least 90% of calories orally) than children randomized to the placebo group.
Aim 2: To assess the safety of 4 weeks of megestrol as part of the 24 week iKanEat protocol.
Hypothesis 2A: Children randomized to the megestrol group will not differ from control children in morning cortisol classification level (low, average, high) and will remain within the normal range at all time points. Analyses 2B: Exploratory analysis will determine which, if any, covariates (gender, age, and diagnoses at week 0, diagnoses at birth) are related to abnormal morning cortisol levels.
Aim 3: To examine the effect of the transition from tube to oral feeding on parent stress and parent and child quality of life. Hypothesis 3A: The transition to oral feeding will temporarily increase parent stress at week 14 at the cessation of tube feeding, with a return to baseline by week 24. Hypothesis 3B: The transition to oral feeding will increase parent/child quality of life at 24 weeks compared to week 0. Children with feeding tubes have few options for treatment other than extensive inpatient stays and expensive day treatment programs. iKanEat offers an outpatient, less intensive, empirically supported effective treatment option that can improve the lives of children and families. It is imperative that the investigators determine the efficacy and safety of the protocol including 4 weeks of megestrol before the investigators move toward broad dissemination of the iKanEat protocol.
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Ann M Davis, PhD, MPH, ABPP
- Phone Number: 913-588-6323
- Email: adavis6@kumc.edu
Study Contact Backup
- Name: Kelsey M Dean, RD, CCRP
- Phone Number: 913-588-3775
- Email: kdean@kumc.edu
Study Locations
-
-
California
-
San Diego, California, United States, 92123
- Recruiting
- Rady Children's Hospital - San Diego
-
Contact:
- Matthew Brigger, MD
- Phone Number: 858-309-7701
- Email: mbrigger@ucsd.edu
-
-
Florida
-
Orlando, Florida, United States, 32806
- Recruiting
- Arnold Palmer Hospital for Children
-
Contact:
- Devendra Mehta, MD
- Phone Number: 321-841-3338
- Email: devendra.mehta@orlandohealth.com
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Recruiting
- Riley Hospital for Children at IU Health
-
Contact:
- Ryan Pitman, MD
- Phone Number: 317-944-3774
- Email: rtpitman@iu.edu
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Recruiting
- Boston Children's Hospital
-
Contact:
- Rachel Rosen, MD
- Phone Number: 617-355-6055
- Email: Rachel.Rosen@childrens.harvard.edu
-
-
Missouri
-
Kansas City, Missouri, United States, 64108
- Recruiting
- Children's Mercy Hospital
-
Contact:
- Sarah Edwards, DO
- Phone Number: 816-234-3000
- Email: sedwards1@cmh.edu
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Recruiting
- Children's Hospital of Philadelphia
-
Contact:
- Hayat Mousa, MD
- Phone Number: 215-913-3906
- Email: MOUSAH@chop.edu
-
-
Rhode Island
-
Providence, Rhode Island, United States, 02903
- Recruiting
- Rhode Island Hospital
-
Contact:
- Carolina S Cerezo, MD
- Phone Number: 401-444-8306
- Email: ccerezo@lifespan.org
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232
- Recruiting
- Monroe Carell Jr. Children's Hospital at Vanderbilt
-
Contact:
- Julia Anderson, MD
- Phone Number: 615-322-7449
- Email: julia.anderson@vumc.org
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Males and females aged 9 months to 9y0m at the time of consent.
- Able to obtain parental or legal guardian written informed consent from subjects as applicable by local laws and regulations.
- Subjects must have a G or G/J tube.
- Subjects must receive over 80% of their total daily calorie needs from a tube in order to be classified as tube dependent.
- Subjects must have a ≥ 3 month history of feeding problems as identified by a diagnosis from a multidisciplinary feeding team, and must have permission from the physician on the team to ensure that they are medically stable enough to participate in a weaning study.
- Subjects must possess the oral motor skills necessary for eating. Subjects must possess behavioral skills necessary for mealtimes.
Exclusion Criteria:
- Children receiving oral or inhaled steroids.
- Parent has a known developmental delay or cognitive impairment that may make participation in the study difficult (children with these issues will not be excluded).
- Children receiving intensive (defined as more than one session per month) behavioral feeding therapy with a licensed psychologist (previous behavioral feeding therapy is not an exclusion criterion; neither is current oral-motor, sensory, or speech therapy).
- Children of non-English speaking parents.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Megestrol
Megestrol is a steroid and progestational drug FDA approved for treating anorexia or weight loss in patients with acquired immunodeficiency syndrome. Its use in the current protocol is "off label" to stimulate appetite in tube-fed infants and toddlers who are weaning from tube feedings and learning to eat. The precise mechanism of action that leads to increased appetite and weight gain is unknown, but is probably related to megestrol's glucocorticoid effect. The proposed study will use megestrol 6 mg/kg/day in two doses because this dose has been effective and safe in two previous studies using megestrol to stimulate appetite in children transitioning from tube to oral feedings. The megestrol will be dosed at full dose weeks 10-11, at 66% dose week 12, at 33% dose week 14, and fully tapered at the end of week 14. Megestrol is absorbed from the small bowel, so feeding it through the tube will be acceptable. |
The proposed study will use megestrol 6 mg/kg/day in two doses because this dose has been effective and safe in two previous studies using megestrol to stimulate appetite in children transitioning from tube to oral feedings.
The megestrol will be dosed at full dose weeks 10-11, at 66% dose week 12, at 33% dose week 14, and fully tapered at the end of week 14.
Megestrol is absorbed from the small bowel, so feeding it through the tube will be acceptable.
Other Names:
The 24 week iKanEat intervention is composed of 4 clinic visits and a series of 12 tele-visits. All visits (clinic and tele-visits) will focus directly on the oral-motor and behavioral skills necessary for oral eating. Tele-visits will begin by building rapport and asking for a summary of all relevant information since the last point of contact, including parent perception of changes in weight, feeding habits, progress, stress of parent/child, and illness. The majority of the time left in the 30 minute session will be spent dealing with parent concerns, which our previous project indicates may include questions about measures, questions about implementation of the iKanEat protocol, and ensuring that children/families adhere to the oral-motor and behavioral guidelines for feeding. |
Placebo Comparator: Placebo
Subjects randomized to the placebo protocol will receive a placebo syrup identical in taste and smell to megestrol at the same intervals as those in the megestrol group but the syrup will contain no active ingredients.
|
The 24 week iKanEat intervention is composed of 4 clinic visits and a series of 12 tele-visits. All visits (clinic and tele-visits) will focus directly on the oral-motor and behavioral skills necessary for oral eating. Tele-visits will begin by building rapport and asking for a summary of all relevant information since the last point of contact, including parent perception of changes in weight, feeding habits, progress, stress of parent/child, and illness. The majority of the time left in the 30 minute session will be spent dealing with parent concerns, which our previous project indicates may include questions about measures, questions about implementation of the iKanEat protocol, and ensuring that children/families adhere to the oral-motor and behavioral guidelines for feeding. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in % kilocalories/day obtained orally
Time Frame: Weeks 0 to 24
|
What percentage of kilocalories come from oral feedings as opposed to g-tube feeding.
|
Weeks 0 to 24
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of patients with adrenal insufficiency as measured by morning cortisol lab value
Time Frame: 10 to 14 weeks
|
The investigators will determine whether any of our participants in either group have adrenal sufficiency levels outside of the normal range at any time point.
Should any participant have levels outside of the normal range, the investigators will descriptively examine the individual characteristics associated with this, including group assignment, medical diagnoses, sex, and age at initiation.
These characteristics will be reported descriptively.
|
10 to 14 weeks
|
Change in parent stress as measured by the Pediatric Inventory for Parents (PIP36)
Time Frame: Weeks 0 to 24
|
The investigators will model parent stress levels from Week 0 to Week 24 of the intervention.
The PIP is scored separately for each of the 4 domains (Communication, Emotional Distress, Medical Care, Role Function), across 2 scales: Frequency (F) and Difficulty (D).
There is also a total score comprised of the sum for each of the 4 domains, yielding Total F and Total D scores.
Items are scored as endorsed by respondents, ranging from 1-5.
The range for each of the Total F and Total D scores is 42-210.
Higher scores are indicative of worse parent stress outcomes.
|
Weeks 0 to 24
|
Change in child quality of life as measured by the Infant Toddler Quality of Life scale (ITQOL47)
Time Frame: Week 0 to 24
|
The investigators will model child quality of life from Week 0 to Week 24 of the intervention.
The Infant Toddler Quality of Life Questionnaire™ (ITQOL) was developed for use in infants and toddlers from 2-months-to-5 years of age.
The Infant Toddler Quality of Life Questionnaire™ (ITQOL) adopts the World Health Organization's definition of health, as a state of complete physical, mental and social wellbeing and not merely the absence of disease.
For each concept, item responses are scored, summed, and transformed on a scale from 0 (worst health) to 100 (best health).
|
Week 0 to 24
|
Collaborators and Investigators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Feeding and Eating Disorders
- Physiological Effects of Drugs
- Antineoplastic Agents
- Antineoplastic Agents, Hormonal
- Contraceptive Agents, Hormonal
- Contraceptive Agents
- Reproductive Control Agents
- Contraceptives, Oral
- Contraceptive Agents, Female
- Contraceptives, Oral, Synthetic
- Contraceptives, Oral, Hormonal
- Central Nervous System Stimulants
- Appetite Stimulants
- Megestrol
- Megestrol Acetate
Other Study ID Numbers
- STUDY00142352
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Feeding Behavior
-
Centre Hospitalier Intercommunal CreteilCompletedFeeding Behavior | Feeding, BottleFrance
-
Sakarya UniversityNot yet recruitingBreast Feeding | Feeding BehaviorTurkey
-
Taipei Medical UniversityCompletedBreast Feeding | Self Efficacy | Feeding BehaviorIndonesia
-
The University of Tennessee, KnoxvilleWithdrawnFeeding Behavior | Behavior | Food Habits | Behavior and Behavior MechanismsUnited States
-
Penn State UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedFeeding BehaviorUnited States
-
Penn State UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed
-
Penn State UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); United...Completed
-
University of Colorado, DenverTemple University; Vitamix FoundationRecruiting
-
Penn State UniversityJenny Craig, Inc.Completed
-
Iowa State UniversityCompleted
Clinical Trials on Megestrol Acetate
-
Southwest Oncology GroupNational Cancer Institute (NCI)CompletedBreast Cancer | Hot Flashes
-
Xiaojun ChenZhejiang Cancer Hospital; Fudan University; Shanghai 6th People's Hospital; Shanghai...CompletedEndometrial Adenocarcinoma | Endometrial Atypical HyperplasiaChina
-
Par Pharmaceutical, Inc.PRA Health SciencesTerminatedAnorexia | Weight Loss | CachexiaUnited States
-
Bristol-Myers SquibbCompletedHIV Infections | Anorexia | CachexiaUnited States
-
Bristol-Myers SquibbCompletedHIV Infections | Anorexia | CachexiaUnited States
-
Endo PharmaceuticalsQuintiles, Inc.CompletedHIV Infections | Anorexia | Cachexia | HIV Wasting Syndrome | AIDS Wasting SyndromeUnited States, India, South Africa
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedAnorexia | Lung Cancer | CachexiaUnited States
-
St. Vincent Medical Center - Los AngelesUnknownBreast Cancer | Malignant Mesothelioma | Endometrial CancerUnited States
-
Northwestern UniversityNational Cancer Institute (NCI)CompletedFatigue | Unspecified Adult Solid Tumor, Protocol Specific | CachexiaUnited States
-
Bristol-Myers SquibbCompletedHIV Infections | Anorexia | CachexiaUnited States